Vitaeris is a clinical stage biopharmaceutical company dedicated to the development of a novel investigational approach to address antibody mediated rejection. Antibody mediated rejection has been recognized as the principal cause of late graft loss in solid organ transplant recipients. Vitaeris' focus is on Clazakizumab, a potent humanized best-in-class monoclonal antibody targeting the cytokine interleukin-6 (IL-6).